

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

agree a paediatric investigation plan and grant a deferral

MHRA-101669-PIP01-24

Scope of the Application

Active Substance(s)

Zerlasiran

Condition(s)

Prevention of cardiovascular events

Pharmaceutical Form(s)

Solution for injection

Route(s) of Administration

Subcutaneous use

Name / Corporate name of the PIP applicant

Silence Therapeutics

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Silence Therapeutics submitted to the licensing authority on 21/03/2025 20:14 GMT an application for a Paediatric Investigation Plan

The procedure started on 30/06/2025 17:16 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

The agreement of a paediatric investigation plan and on the granting of a deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-101669-PIP01-24

Of 23/03/2026 09:02 GMT

On the adopted decision for Zerlasiran (MHRA-101669-PIP01-24) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on a paediatric investigation plan

This decision applies to a Paediatric Investigation Plan for Zerlasiran, Solution for injection , Subcutaneous use .

This decision is addressed to Silence Therapeutics, Robert-Rossle-Strasse 10, Berlin, GERMANY, 13125

ANNEX I

1. Waiver

1.1 Condition:

Not applicable

2. Paediatric Investigation Plan:

2.1 Condition(s):

Prevention of cardiovascular events

2.2 Indication(s) targeted by the PIP:

For the prevention of cardiovascular events in paediatric patients with high lipoprotein(a) concentrations

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

All subsets of the paediatric population from birth to less than 18 years of age

2.4 Pharmaceutical Form(s):

Solution for injection

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of an age-appropriate formulation and/or strength(s) to cover the paediatric population included in the PIP. To discuss with the Regulatory Agency, via a modification procedure, the need for the study once the population in the PIP and paediatric doses are determined, no later than 6 months after completion of the phase 3 adult study (SLN360-003).
Non-Clinical Studies	0	Not applicable.
Clinical Studies	1	Study 2 Clinical study to investigate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of zerlasiran in paediatric patients with elevated lipoprotein(a) from birth to less than 18 years of age. The final study design, objectives and the population to be included in the study (including age ranges, inclusion/exclusion criteria and Lp(a) threshold for enrolment) together with the possibility of dividing the population into separate studies must be decided and rediscussed with the Regulatory Agency via a modification procedure before its initiation once phase 3 adult study (SLN360-003 study) is completed and after the applicant has sought advice from experts in the field.
Extrapolation, Modeling & Simulation Studies	2	Study 3 The modelling and simulation analysis to be conducted in support of the paediatric

		development must be agreed with the Regulatory Agency after completion of the Phase 3 adult study (SLN360-003 study) and prior to the initiation of Study 2. Extrapolation Plan The possible extrapolation of efficacy must be discussed and agreed with the Regulatory Agency prior to the initiation of Study 2 after completion of the Phase 3 adult study (SLN360-003 study) and after the applicant has sought advice from experts in the field.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	31/12/2036
Deferral of one or more studies contained in the paediatric investigation plan:	Yes